Biosimilar to Lucentis approved to treat neovascular age-related macular degeneration, macular edema, myopic choroidal neovascularization
Semglee (insulin glargine-yfgn) is biosimilar to and interchangeable with Lantus (insulin glargine), provides cost-effective option
The Food and Drug Administration approved its first biosimilar product in March, opening the door for more costly drug alternatives.
The Food and Drug Administration approved its first biosimilar product last week, opening the door for more costly drug alternatives.
Please login or register first to view this content.
Login Register